1. Scrip
  2. >>Business
  3. >>Earnings

Bristol’s 2025 Guidance Falls Short, But CEO Boerner Warned This Was Coming

$2bn In Cost Cuts Planned; Medicare Redesign Neutral

 
• By Mandy Jackson

Boerner warned a year ago that BMS may see its revenue falter in the middle of this decade and the company’s 2025 guidance suggests that will happen this year after 2024 beat consensus.

BMS forecast an almost $3bn revenue decline in 2025 (Shutterstock)

CEO Christopher Boerner warned at the J.P. Morgan Healthcare Conference in January 2024, two months into his tenure as chief exec of Bristol Myers Squibb, that the company would navigate a few years of losses of exclusivity for key products between 2025 and 2030, with a return to revenue growth later in the decade. That scenario played out on 6 February when BMS reported good 2024 revenue growth, but its 2025 guidance suggests a nearly $3bn year-over-year decline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Scrip

Merck KGaA Moves Closer To Sealing SpringWorks Buy

 
• By Kevin Grogan

The German group could pay $3.5bn to get hold of the US firm and its two approved products.

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.